Search

Your search keyword '"ANTIBODY formation"' showing total 17,700 results

Search Constraints

Start Over You searched for: Descriptor "ANTIBODY formation" Remove constraint Descriptor: "ANTIBODY formation" Topic female Remove constraint Topic: female
17,700 results on '"ANTIBODY formation"'

Search Results

1. High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.

2. Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis

3. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response

4. Global absence and targeting of protective immune states in severe COVID-19

5. Microbiome for Mars: surveying microbiome connections to healthcare with implications for long-duration human spaceflight, virtual workshop, July 13, 2020.

6. Fine-scale heterogeneity in Schistosoma mansoni force of infection measured through antibody response

7. Estradiol, progesterone, immunomodulation and COVID-19 outcomes

8. Chlamydia trachomatis L2c Infection in a Porcine Model Produced Urogenital Pathology and Failed to Induce Protective Immune Responses Against Re-Infection

9. CD8 Treg Cells Inhibit B-Cell Proliferation and Immunoglobulin Production

10. Distinct Antibody Signatures Associated with Different Malaria Transmission Intensities in Zambia and Zimbabwe

11. B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells

12. Blimp-1–dependent and –independent natural antibody production by B-1 and B-1–derived plasma cells

13. Persistent Herpesvirus Infections and Telomere Attrition Over 3 Years in the Whitehall II Cohort.

14. Plasma and Mucosal Immunoglobulin M, Immunoglobulin A, and Immunoglobulin G Responses to the Vibrio cholerae O1 Protein Immunome in Adults With Cholera in Bangladesh

15. Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients

16. Siderophore-based immunization strategy to inhibit growth of enteric pathogens

17. Genome-Scale Protein Microarray Comparison of Human Antibody Responses in Plasmodium vivax Relapse and Reinfection

18. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities

19. Cutting Edge: AIM2 and Endosomal TLRs Differentially Regulate Arthritis and Autoantibody Production in DNase II–Deficient Mice

20. Impact of acute malaria on pre-existing antibodies to viral and vaccine antigens in mice and humans.

21. Lack of Evidence for Molecular Mimicry in HIV-Infected Subjects

22. CD4+ T Cells Promote Antibody Production but Not Sustained Affinity Maturation during Borrelia burgdorferi Infection

23. Histone Deacetylase Inhibitors Upregulate B Cell microRNAs That Silence AID and Blimp-1 Expression for Epigenetic Modulation of Antibody and Autoantibody Responses

24. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination

25. A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis.

26. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers

27. Human cytomegalovirus non-primary infection during pregnancy: antibody response, risk factors and newborn outcome

28. Maternal Immunization Programs Postnatal Immune Responses and Reduces Atherosclerosis in Offspring

29. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis

30. Effect of Water Polo Practice on Cytokines, Growth Mediators, and Leukocytes in Girls

31. Antibody response to an accelerated course of Hepatitis B vaccination

32. Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study

33. SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19:An ISARIC4C prospective study

34. Complex sex-biased antibody responses: estrogen receptors bind estrogen response elements centered within immunoglobulin heavy chain gene enhancers.

35. SARS‐CoV‐2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine

36. Plasma Endogenous Endotoxin Core Antibody Response to Exercise in Endurance Athletes

37. Humoral antibody response to the first dose of the <scp>ChAdOx1 nCoV</scp> ‐19 vaccine in Asian patients undergoing hemodialysis

38. Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers

39. Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study

40. SARS-CoV-2 anti–spike antibodies after vaccination in pediatric heart transplantation: A first report

41. Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset

42. Antibody responses to inactivated SARS‐CoV‐2 vaccine in peritoneal dialysis patients

43. Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody

44. Distinct kinetics of antibodies to 111 Plasmodium falciparum proteins identifies markers of recent malaria exposure

45. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas

46. Do the Kinetics of Antibody Responses Predict Clinical Outcome in Hospitalized Patients With Moderate-to-Severe COVID-19?

47. Antibody Response to an mRNA SARS-CoV-2 Vaccine Following Initial Vaccination With Ad.26.COV2.S in Solid Organ Transplant Recipients: A Case Series

48. SARS-CoV-2 Antibody Response After ChAdOx1 nCoV-19 Vaccination in Persons With Previous SARS-CoV-1 Infection

49. SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents

50. Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response

Catalog

Books, media, physical & digital resources